G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 120 filers reported holding G1 THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 58.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,333,117 | -32.4% | 925,776 | +16.9% | 0.00% | -50.0% |
Q2 2023 | $1,972,364 | -1.5% | 792,114 | +6.0% | 0.00% | 0.0% |
Q1 2023 | $2,003,061 | -26.1% | 747,411 | +49.8% | 0.00% | 0.0% |
Q4 2022 | $2,709,043 | -54.8% | 498,903 | +4.0% | 0.00% | -66.7% |
Q3 2022 | $5,991,000 | +176.8% | 479,635 | +9.5% | 0.01% | +200.0% |
Q2 2022 | $2,164,000 | -28.4% | 438,156 | +10.1% | 0.00% | -33.3% |
Q1 2022 | $3,024,000 | +28.0% | 397,879 | +72.0% | 0.00% | +50.0% |
Q4 2021 | $2,362,000 | +30.6% | 231,315 | +71.7% | 0.00% | 0.0% |
Q3 2021 | $1,808,000 | -37.9% | 134,739 | +1.6% | 0.00% | -33.3% |
Q2 2021 | $2,910,000 | -1.4% | 132,648 | -0.7% | 0.00% | 0.0% |
Q1 2021 | $2,950,000 | +13.1% | 133,520 | -7.9% | 0.00% | 0.0% |
Q4 2020 | $2,608,000 | +37.3% | 144,953 | -11.9% | 0.00% | +50.0% |
Q3 2020 | $1,900,000 | -48.7% | 164,517 | +7.7% | 0.00% | -60.0% |
Q2 2020 | $3,707,000 | +2889.5% | 152,788 | +1253.9% | 0.01% | – |
Q1 2020 | $124,000 | -46.8% | 11,285 | +28.0% | 0.00% | – |
Q4 2019 | $233,000 | – | 8,819 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Cormorant Asset Management, LP | 994,287 | $19,041,000 | 1.55% |
HHLR ADVISORS, LTD. | 949,431 | $18,182,000 | 0.75% |
BB BIOTECH AG | 671,925 | $12,867,000 | 0.41% |
Rhenman & Partners Asset Management AB | 172,820 | $3,310,000 | 0.38% |
Birchview Capital, LP | 15,000 | $287,000 | 0.27% |
Rock Springs Capital Management LP | 100,000 | $1,915,000 | 0.09% |
SECOR Capital Advisors, LP | 32,591 | $624,000 | 0.08% |
MARSHALL WACE, LLP | 386,510 | $7,402,000 | 0.08% |
SIGNATUREFD, LLC | 37,942 | $727,000 | 0.07% |
A.R.T. Advisors, LLC | 38,125 | $730,000 | 0.05% |